Connect with us

Stocks to Watch

Will Amazon Stock Price Rebound After The Underperformance?

Joe Samuel

Published

on

amazon stock price

Amazon.com, Inc. (AMZN Stock Report) has been on a roll for the better part of the last decade. Although it has been a difficult year for the financial markets, the e-commerce giant has still managed to surge by as much as 19% this year. However, in August, the stock is down by 13.5% although the broader market has declined by 4.5%.

The August performance has proven to be a bit of a shock for the company. Although Amazon seems impervious to market dynamics, bearish cycles can eventually affect the biggest companies in the world. Therefore, it is worthwhile to have a look at some of the factors that could weigh down the Amazon stock.

Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key [REPORT]

Amazon Stock Price: Key Drivers

amazon stock price

First and foremost, the authorities in the United States have started serious anti-trust action against the biggest tech companies in the world. Along with Facebook (FB Stock Report) and Apple (AAPL Stock Report), Amazon is also one of the companies that is under the scanner. In the end, the proceedings might not end up breaking up the company as many critics have suggested. But it will create a degree of uncertainty that might force investors to give up the stock. Uncertainty is something that the market does not like and anti-trust action is something that could create chaos.

Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key [REPORT]

Over the years, the company’s cloud computing arm Amazon Web Services has been its cash cow. It allows Amazon to plow more money into its other operations that tend to lose money. However, competition is heating up in the cloud computing industry and some of the biggest names in tech have entered the fray. Microsoft (MSFT Stock Report) is gearing up to give stiff competition with its Azure service, while IBM (IBM Stock Report) has also come up with its own product. It is inevitable that it will result in a loss of market share and lowering of prices.

Last but not least, it is still not clear which is going to be the area in which the company is going to deliver the sort of growth it had generated in cloud or e-commerce.

Continue Reading
Click to comment

Featured

Stock Price Newsletter – September 18, 2019

Joe Samuel

Published

on

biotech stock to watch 2019

4 Penny Stocks Catching Attention This Week

Several economic and sector events have sparked interest in a number of small-cap and micro-cap stocks this week.

See For Yourself


Airline Stocks In Focus; Spur Interest In Detection Tech Companies?

The latest mix of attacks and focus on airlines could have a different impact on sectors like weapons detection & defense. What could this mean for stocks to watch this week?

Click Here To Read More


Top Biotech Stocks To Watch This Week

The values of biotech equities, however, do generally start to pick up as the year winds down. The underlying reason is that the latter part of the year is chock-full of key data readouts, regulatory decisions, and thousands of scientific conferences across the globe. 

Click Here To Read More

Click Here For Full Disclaimer

Continue Reading

News

SNAP Stock Price Surging Big In 2019, Here Are Key Drivers

Joe Samuel

Published

on

Snap Inc (SNAP Stock Report) has had an exceptional 2019 and has seen its stock gain 190% year-to-date. Snap continues to perfume well and has outpaced the growth of peers such as Twitter and Facebook.

Evan Spiegel, the CEO of the company, has been selling millions of Snap’s stock, and last week he sold stock worth more than $33 million. It seems this is the trend currently as both Amazon CEO, Jeff Bezos, and Facebook CEO, Mark Zuckerberg, have also been selling shares of their companies.

[Read More] Airline Stocks In Focus; Spur Interest In Detection Tech Companies?

After a torrid 2018, fundamentals of Snap are slowly improving and uses base has continued to grow steadily. Here are things to consider if the stock is worth buying.

Improving User Base Growth

Last year the company’s user base struggled, but things have changed this year. In the first quarter, the company added 4 million daily active users, and in the second quarter, the company grew users to 13 million.

Currently, the company boasts 500 million active users, and this is a result of the company’s updated version of its app and more focus on AR technology. Recently the company said it would partner with Spotify to allow users to share podcasts and music directly in the app.

Avoiding Regulatory Issues

This year the company has managed to avoid much of the criticism it endured last year with top executives leaving. It has also avoided regulatory issues that tech companies such as Facebook have faced in recent times. For instance, Facebook has faced criticism over its cryptocurrency project Libra and recently FTC fined Facebook $5 billion.

Introduction of Gaming

Although the company’s advertising business is doing well, they are nonetheless focusing on gaming business as a new source of revenue. In April, Snap launched Snap Games which caught the attention of Zynga which introduced a new battle royale game on the platform. Gaming could bring the company millions in sales revenue in 2020.

The company’s Q3 revenue guidance shows that the company expects revenue to range from $410 million to $435 million.

Continue Reading

Biotechnology

3 Biotech Stocks Jumped Big Last Month

Joe Samuel

Published

on

biotech stocks to buy

The biotech sector has thrown up a high number of gems over the years and helped generate hefty returns for investors. Due to the advancements made in biotechnology over the years and those which are still being made, it is a sector that will continue to be a favorite of many investors.

Plenty of companies are doing revolutionary work in this space and have the potential of turning into excellent investments eventually. Here is a look at 3 biotech stocks that jumped significantly over the past few weeks and deserve to be on the watch lists of investors.

Tiziana Life Sciences (TLSA)

This biotech stock has been riding under the radar for the better part of the last 6 months. But in September, shares of Tiziana Life Sciences (TLSA) have enjoyed a much more active market. This has been due, in part to recent Phase Trial news related to the company’s pipeline therapies:

[9/16/19] Tiziana Life Sciences (TLSA) Announces FDA Approval to Initiate Phase I Clinical Trial with Orally Administered Foralumab in Healthy Volunteers

[9/10/19] Tiziana Reports Phase 1 Clinical Data Demonstrating Nasal Treatment with Foralumab was Well-tolerated and Produced Positive Trend in Biomarkers of Immunomodulation and Anti-inflammation in Healthy Volunteers

[9/4/19] Tiziana Life Sciences (TLSA) Reports Positive Phase 2a Clinical Data Exhibiting Positive Clinical Activity with Milciclib Monotherapy in Advanced Sorafenib-refractory or -intolerant Patients with Unresectable or Metastatic Hepatocellular Carcinoma

Tiziana Life Sciences (TLSA) is focusing on to develop novel treatment for liver diseases such as NASH and hepatocellular carcinoma (HCC). Tiziana (TLSA) holds extensive IP and a strong pipeline of in-licensed clinical assets. Tiziana has clinical development programs for Foralumab and Milciclib. Strong IP for oral and nasal administration is for the platform technology, which is applicable to all antibodies drugs for treatment of human diseases. Click To Read More About Tiziana Life Sciences (TLSA)

Mesoblast (MESO)

The next company to watch: Mesoblast Limited (MESO Stock Report). Its shares skyrocketed last week after it emerged that it had entered into a lucrative partnership with Grunethal. Grunethal is a privately held German company. According to the terms of the deal, the companies are focusing on the development as well as sales of the product MPC-06-ID.

According to the terms of the deal, Grunethal is going to pay $15 million to Memoblast straightaway for the right to sell the medicine in South America and Europe. However, the company stands to earn as much as $135 million more if certain targets are met. The Phase 3 trials for patients in the United States are already happening and the data could be available by mid-2020.

Kodiak Science (KOD)

The other stock which made a major move last week was Kodiak Science (KOD Stock Report). The company is involved in AMD or age-related macular degeneration and similar other conditions that hamper the vision in people of advanced age.

Vision loss is one of the most important categories of treatments in the sector and there is a lot of conflict in the sector with regards to the effectiveness of anti-VEGF medicines. Kodiak is developing its own antibody known as KSI-301and recently human proof of concept data points with regards to the anti-VEGF medicine showed that the company might have actually found something that could work. That resulted in the remarkable rise in the stock price last week.

biotech stocks to watch
Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Tiziana Life Sciences plc (TLSA), Midam has been paid $150,000 by Tiziana Life Sciences plc (TLSA) for a period from August 22, 2019 to September 22, 2019. We may buy or sell additional shares of Tiziana Life Sciences plc (TLSA) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Tiziana Life Sciences plc (TLSA). Full Disclaimer Click Here

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com